The fact is, Lilly isn't even the largest profiteer. The insane margins of insulin are actually split between Lilly, PBMs (like optumRX and CareMark) and insurance companies, through an incredibly complex system of rebates and vouchers. Turning over that rock reveals more writhing maggots than anyone cares to see.
